Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 8.


Semple, Malcolm G ORCID: 0000-0001-9700-0418, Myles, Puja R, Nicholson, Karl G, Lim, Wei Shen, Read, Robert C, Taylor, Bruce L, Brett, Stephen J, Openshaw, Peter JM, Enstone, Joanne E, McMenamin, James
et al (show 2 more authors) (2013) An Evaluation of Community Assessment Tools (CATs) in Predicting Use of Clinical Interventions and Severe Outcomes during the A(H1N1)pdm09 Pandemic. PLOS ONE, 8 (9). e75384-.


Collini, Paul J, Bewley, Martin A, Mohasin, Mohamed, Marriott, Helen M, Miller, Robert F, Geretti, Anna-Maria ORCID: 0000-0002-3670-6588, Beloukas, Apostolos ORCID: 0000-0001-5639-0528, Papadimitropoulos, Athanasios ORCID: 0000-0001-9822-4931, Read, Robert C, Noursadeghi, Mahdad
et al (show 1 more authors) (2018) HIV gp120 in the Lungs of Antiretroviral Therapy-treated Individuals Impairs Alveolar Macrophage Responses to Pneumococci. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 197 (12). pp. 1604-1615.


Liu, Xinxue, Wright, Annie, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baker, Jonathan, Baxter, David, Bawa, Tanveer, Bula, Marcin
et al (show 50 more authors) (2023) Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. JOURNAL OF INFECTION, 87 (1). pp. 18-26.


Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 48 more authors) (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. JOURNAL OF INFECTION, 84 (6). pp. 795-813.


Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 48 more authors) (2023) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial (vol 84, pg 795, 2022). JOURNAL OF INFECTION, 86 (5). pp. 540-541.


Munro, Alasdair PS, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate
et al (show 44 more authors) (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. LANCET, 398 (10318). pp. 2258-2276.


Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 45 more authors) (2022) Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. LANCET INFECTIOUS DISEASES, 22 (8). pp. 1131-1141.


Killingley, Ben, Mann, Alex J, Kalinova, Mariya, Boyers, Alison, Goonawardane, Niluka, Zhou, Jie, Lindsell, Kate, Hare, Samanjit S, Brown, Jonathan, Frise, Rebecca
et al (show 21 more authors) (2022) Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. NATURE MEDICINE, 28 (5). 1031-+.

This list was generated on Mon Feb 12 09:09:22 2024 GMT.